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Myelodysplastic syndromes (MDS) with ring sideroblasts are hematopoietic stem cell disorders with erythroid 
dysplasia and mutations in the SF3B1 splicing factor gene. Patients with MDS with SF3B1 mutations often accumulate 
excessive tissue iron, even in the absence of transfusions, but the mechanisms that are responsible for their 
parenchymal iron overload are unknown. Body iron content, tissue distribution, and the supply of iron for eryth-
ropoiesis are controlled by the hormone hepcidin, which is regulated by erythroblasts through secretion of the 
erythroid hormone erythroferrone (ERFE). Here, we identified an alternative ERFE transcript in patients with MDS 
with the SF3B1 mutation. Induction of this ERFE transcript in primary SF3B1-mutated bone marrow erythroblasts 
generated a variant protein that maintained the capacity to suppress hepcidin transcription. Plasma concentrations 
of ERFE were higher in patients with MDS with an SF3B1 gene mutation than in patients with SF3B1 wild-type 
MDS. Thus, hepcidin suppression by a variant ERFE is likely responsible for the increased iron loading in patients 
with SF3B1-mutated MDS, suggesting that ERFE could be targeted to prevent iron-mediated toxicity. The expression 
of the variant ERFE transcript that was restricted to SF3B1-mutated erythroblasts decreased in lenalidomide- 
responsive anemic patients, identifying variant ERFE as a specific biomarker of clonal erythropoiesis.
INTRODUCTION
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) are 
clonal hematopoietic stem cell (HSC) disorders with a prominent 
erythroid dysplasia of the bone marrow (BM) responsible for a 
macrocytic anemia. Mitochondrial iron accumulation and apoptosis 
of mature erythroblasts cause ineffective erythropoiesis (1, 2). In 
contrast to other MDS subtypes, patients with MDS-RS exhibit 
signs of systemic iron accumulation that is reflected by increased 
ferritin and nontransferrin bound iron concentrations even before 
they become transfusion dependent and subsequently develop pa-
renchymal iron overload (3, 4).
Splicing factor gene SF3B1 is mutated in ~90% of MDS-RS, and 
the diagnosis is considered whenever the gene is mutated, although 
the percentage of RS is relatively low, between 5 and 15% (5–7). 
These mutations arise in the HSCs (8–10). Aberrant splicing events 
are reported in MDS and other SF3B1-driven cancers, including 
uveal melanoma and chronic lymphocytic leukemia (CLL) (11–14). 
The selection of an alternative branch site resulting in the use of a 
cryptic 3′ splice site (ss) is the most frequently detected abnormality. 
Computational analysis revealed that most of the cryptic 3′ss are 
located upstream of canonical 3′ss at nucleotide distances that are 
not multiples of 3, suggesting that the aberrant transcripts would 
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likely contain a premature termination codon (PTC) and be degraded 
by nonsense-mediated decay (NMD). It has been predicted that half 
of the aberrantly spliced transcripts in SF3B1-mutated cells are NMD 
sensitive and that the canonical isoforms are down-regulated (11). 
For instance, ABCB7 transcript encoding a mitochondrial transporter 
involved in the export of Fe-S clusters is aberrantly spliced and under-
goes NMD. It is also possible that NMD-insensitive aberrant tran-
scripts are translated into proteins with altered function (11). Globally, 
missplicing may contribute to defective messenger RNA (mRNA) 
production and deregulation of cellular pathways (15, 16). How these 
aberrant splicing events contribute to the disease phenotype and in 
particular to systemic iron overload is unclear.
In contrast with other MDS subtypes, MDS-RS are associated 
with lower expression of the iron homeostasis regulator, hepcidin, 
and as a consequence, the absorption of iron by duodenal enterocytes 
and its release from erythrophagocytic macrophages may be increased 
(17–22). Inappropriately low hepcidin concentrations in MDS-RS 
could depend on the degree of ineffective erythropoiesis linked to 
impaired iron incorporation into heme because of mitochondrial 
iron trapping and/or to increased expression of hepcidin repressors 
(23). Growth differentiation factor 15 (GDF-15) and twisted gastru-
lation (TWSG1), two members of the transforming growth factor– 
superfamily, have been proposed as pathological suppressors of 
hepcidin in ineffective erythropoiesis (24, 25). More recently, ery-
throferrone (ERFE), a C1q–tumor necrosis factor–related family of 
proteins (CTRP) member, has been described as a major erythroid 
regulator of hepcidin, involved in the pathological suppression of 
hepcidin in patients with -thalassemia (26, 27).
In the present study, we identify a variant transcript of ERFE 
specific to SF3B1-mutated MDS. The expression of the variant 
ERFE is restricted to the erythroid lineage, and the variant contributes 
to increased concentration of ERFE protein, resulting in hepcidin 
suppression and systemic iron accumulation in patients. This variant 
appears to be a pertinent biomarker of clonal erythropoiesis with 
potential use for monitoring treatment response of anemic patients 
with SF3B1-mutated MDS.
RESULTS
Up-regulation of ERFE using an alternative 3′ss  
in SF3B1-mutated MDS
To investigate the mechanism of systemic iron overload, we estab-
lished a cohort of 156 patients with lower-risk MDS, including 60 MDS- RS 
with single lineage dysplasia (SLD), 17 MDS-RS with multi lineage 
dysplasia (MLD), 2 5q-syndrome, 17 MDS-SLD, 42 MDS-MLD, and 18 
MDS with type 1 excess of blasts (EB1) (table S1). The Revised In-
ternational Prognostic Scoring System score was very low in 15, 
low in 95, intermediate in 36, and high in 4 patients. Twenty-six 
genes commonly mutated in MDS were sequenced in the BM 
mononuclear cell (MNC) fraction. The SF3B1 gene was mutated in 
94 patients with MDS, including 63 (67%) affected by an SF3B1K700E 
mutation. Among the 62 patients with no SF3B1 mutation, other 
splicing genes, SRSF2, U2AF1, or ZRSR2, were mutated in 27 cases, 
and no splicing gene mutation was observed in 35 cases. Some pa-
tients presented with two splicing mutations (fig. S1). We evaluated 
the consequences of SF3B1 gene mutations on gene expression and 
splicing by sequencing the transcriptome of the BM MNCs isolated 
from 27 patients in this cohort, including 21 with SF3B1MUT MDS, 
6 with SF3B1WT MDS, and 5 healthy controls. Differential analyses 
of gene expression and splice junctions were conducted using 
DESeq2 (28). We detected 6343 genes as differentially expressed be-
tween SF3B1MUT MDS and SF3B1WT MDS with P < 0.05 (data file S1). 
Principal components analysis of gene expression profiles separated 
SF3B1MUT and SF3B1WT MDS (Fig. 1A). The differentially expressed 
genes were enriched in 73 specific gene ontology (GO) terms with 
an absolute log2 fold change (FC) > 1 and a Benjamini-Hochberg 
(BH)–adjusted P value < 0.05 (Fig. 1B). Genes with log2(FC) < −1 
were involved in serine/threonine kinase signaling, apoptosis, myeloid 
differentiation, inflammation, and cell-cell adhesion, whereas those 
with a log2(FC) > 1 were involved in heme metabolism, erythrocyte 
differentiation, and iron homeostasis (Fig. 1C). We plotted the 
log2(FC) of 16 differentially expressed genes belonging to the 
IRON_ION_HOMEOSTASIS gene set (GO:0055072; http://amigo.
geneontology.org) and showed that the FAM132B/ERFE transcript 
encoding ERFE was increased (Fig. 1D). The FAM132B/ERFE tran-
script was similarly expressed in samples with an epigenetic TET2MUT/ 
DNMT3AWT/ SF3B1WT genotype compared to healthy controls or 
with a DNMT3AMUT/TET2WT/SF3B1MUT compared to DNMT3AWT/ 
TET2WT/ SF3B1MUT genotype, suggesting that the deregulation of 
ERFE transcript expression was linked to SF3B1 mutation (table S2).
We then identified 1528 differentially expressed 5′ and 3′ junc-
tions, including annotated 5′ donor and 3′ acceptor ss, ambiguous 
junctions, and canonical junctions with BH-adjusted P values ≤ 10−5 
and absolute log2(FC) ≥ 1 (data file S2). These junctions allowed 
the hierarchical clustering of the 21 SF3B1MUT and 6 SF3B1WT MDS 
samples (Fig. 2A). After excluding differentially expressed canonical 
junctions, we then considered the 1147 alternative junctions, among 
which we identified 786 3′ acceptor junctions (68.5%), 176 5′ donor 
junctions (15.3%), and 185 ambiguous junctions (16.1%) attributed 
to either the alternative 5′ or 3′ss or both alternative 5′ and 3′ss 
(Fig. 2B). The analysis of distances between the alternative and ca-
nonical 3′ss showed that most of the alternative 3′ss (AG′) were 
located between −24 and −9 nucleotides (nt) preceding the canonical 
3′ss (AG) (Fig. 2C). The proportion of alternative AG′ junctions in 
these novel splice variants generally increased in SF3B1 mutants 
and less frequently in SF3B1WT samples (Fig. 2D). To detect alternative 
transcripts that were likely to generate substantial amounts of variant 
proteins with a modified length, we applied a filter selecting tran-
scripts with an additional stretch of nucleotides numbering in mul-
tiples of 3, a ratio of alternative junction coverage (AG′) to alternative 
and canonical junctions coverage (AG′ + AG) of more than 0.1, and 
an expression ratio of the alternative junction in SF3B1MUT versus 
SF3B1WT samples of more than 10 (fig. S2A). We obtained 66 alter-
native junctions in 63 genes (data file S3 and fig. S2B). These genes 
were involved in epigenetic regulation and transcription, mRNA 
processing and translation, intracellular transport, cell cycle and 
migration, signaling and apoptosis, mitochondrial metabolism, and 
iron homeostasis (Fig. 2E). Among the 66 alternative junctions, 29 were 
related to an in-frame insertion of 9 to 27 nt, and 26 of them were 
differentially expressed between SF3B1MUT and SF3B1WT MDS with 
an absolute log2(FC) > 0.3 (Fig. 2F). The FAM132B/ERFE gene was 
identified among the up-regulated genes with an alternative junction 
due to the use of a cryptic 3′ss located between exons 2 and 3 (chr2: 
239,070,357 to 239,071,364) and no PTC. The aberrant transcript con-
tained 12 additional nucleotides in the open reading frame and from 
here on is referred to as ERFE+12 (Fig. 2G). It was systematically de-
tected in all SF3B1MUT MDS samples and represented a mean percent-
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0.2% in SF3B1WT MDS. The mutation pattern of samples expressing 
ERFE+12 is shown in fig. S2C. This indicates that the expression of ERFE+12 
was strongly linked to the presence of a mutation in the SF3B1 gene.
SF3B1MUT-restricted expression of alternative  
ERFE+12 transcript
To ascertain that expression of the ERFE+12 transcript is dependent on the 
presence of an SF3B1 mutation, we transfected the erythromegakaryo-
cytic cell line UT7/erythropoietin (EPO) with a pLVX plasmid 
encoding a synthetic full-length SF3B1WT or mutant SF3B1K700E 
complementary DNA (cDNA). We then designed a sensitive fluo-
rescent polymerase chain reaction (PCR) allowing the detection of 
ERFE+12 and ERFEWT transcripts as 162- and 150-nt fragments by 
capillary electrophoresis (table S3). Twenty-four hours after 
transfection, ERFE+12 transcript was detected in SF3B1K700E-transfected 
cells but not in SF3B1WT cells (Fig. 3A). To validate the splice pattern 
induced in the context of SF3B1 mutation in ERFE pre-mRNA, 
we performed a minigene splicing assay. 
An ERFE sequence of about 200 nt 
located on both sides of the cryptic 3′ss 
(AG′) was cloned in an Exontrap vector. 
The alternative junction in ENOSF1 
gene (chr18: 683,395 to 685,920) cloned 
in the same vector was used as a control 
(13). These minigenes were transfected 
into the murine G1E-ER4 cell line in 
which the SF3B1K700E mutation was 
edited by CRISPR-Cas9 technology. As 
expected due to the lack of intron ho-
mology between species, sequencing the 
transcriptome of G1E-ER4 SF3B1K700E cell 
line or isogenic SF3B1WT cell line demon-
strated that endogenous murine ERFE 
and ENOSF1 did not undergo alterna-
tive splicing (12). After transfection, the 
alternative 3′ss AG′ ERFE+12 was detected 
by capillary electrophoresis in G1E-ER4 
SF3B1K700E cells but not in the isogenic 
G1E-ER4 SF3B1WT or parental cells 
(Fig. 3B). The usage of alternative 3′ss 
AG′ was detectable for ENOSF1 gene in 
the SF3B1WT cell line and became 
predominant in the SF3B1K700E cell line, 
suggesting that the mutation favored 
the usage of alternative AG′. Then, we 
performed a rescue experiment by add-
ing a destabilization domain (DD) tag 
to the mutant SF3B1R625G allele in the 
Mel202 cell line, as previously described 
(29). The DD-tagged protein is stabi-
lized by interaction with the DD ligand 
Shield-1 and is degraded upon Shield-1 
withdrawal. In Mel202 clone 26 con-
taining one DD-tagged SF3B1R625G allele, 
Shield-1 removal abrogated ERFE+12 
expression. This supports a causal relation-
ship between SF3B1 mutation and the ab-
errant splicing isoform of ERFE (fig. S3).
We then investigated the expression of 
ERFEWT and ERFE+12 in primary BM samples of patients with MDS 
using fluorescent PCR and real-time quantitative PCR (RT-qPCR) 
(table S3). Among 46 patients with lower-risk MDS, SF3B1MUT was 
present in 25 patients, including 20 with MDS-SLD-RS/MDS-MLD-RS, 
3 with MDS-MLD, and 2 with MDS-EB1. By fluorescent PCR, 
ERFE+12 was detected in the BM MNC fractions of all SF3B1MUT 
MDS. ERFE+12 was not detected in any other cases of MDS with 
mutations in SRSF2 (n = 10), U2AF1 (n = 1), or ZRSR2 (n = 1), or in 
9 patients with MDS with mutations in other genes, as shown in 
Fig. 3C and table S4. ERFEWT and ERFE+12 mRNA amounts mea-
sured by RT-qPCR were up-regulated in SF3B1MUT samples com-
pared to any SF3B1WT samples with other splicing or epigenetic 
mutations or without recurrent mutation (Fig. 3D and table S4). 
In one patient with an SF3B1 monoallelic deletion and a G742D 
substitution on the remaining allele, the expression of alternative 
ERFE+12 exceeded that of the canonical ERFEWT (fig. S4). We then 
amplified primary erythroblasts from the BM CD34+ cells of two 
Fig. 1. Differential gene expression in SF3B1MUT MDSs. (A) Biplot of the first two principal components (PCs) showing 
45.4% of the variability within the data (PC1, x axis; PC2, y axis). (B) Volcano plot showing differentially expressed tran-
scripts in SF3B1MUT BM MNCs compared to SF3B1WT BM MNCs. Fold change (FC) on the x axis and negative log10 of 
Benjamini-Hochberg (BH) corrected P values on the y axis. Dotted vertical and horizontal lines reflect the filtering criteria 
(FC < 0.5 or > 2.0; and BH-corrected P value < 0.05). The red dots represent differentially up-regulated transcripts, the 
blue dots represent differentially down-regulated transcripts, and the gray dots represent transcripts without differential 
expression. (C) GO enrichment analysis of differentially expressed genes with an absolute log2 (FC) >1 and a P value < 
0.05 in SF3B1MUT MDS. The most down-regulated and up-regulated gene sets are represented. (D) Log2(FC) of the expres-
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patients with SF3B1MUT and one patient 
with SF3B1WT MDS and showed that 
ERFE+12 was expressed in SF3B1MUT but 
not in SF3B1WT erythroid cells (Fig. 3E). 
This further supports the idea that ERFE+12 
is related to SF3B1 mutation. SF3B1MUT 
MDS are characterized by the enrich-
ment of the BM with erythroid cells. To 
investigate whether ERFE+12 could be 
detected in cells derived from erythro-
blastic BM with another genetic back-
ground, we collected samples from one 
patient with MDS-RS with 38% of BM 
erythroblasts, more than 15% of RS, a 
normal karyotype, and no SF3B1 muta-
tion but one SRSF2 and one TET2 mu-
tation; three patients with a congenital 
sideroblastic anemia due to an ALAS2 
mutation/deletion or a GLRX5 mutation; 
one patient with a severe -thalassemia; 
and one patient with SF3B1K700E MDS. 
By fluorescent PCR, ERFEWT was pre-
sent, whereas ERFE+12 was not detect-
able in any sample except the SF3B1K700E 
MDS (Fig. 3F). This confirms that the 
onset of an aberrant ERFE+12 is depen-
dent not on the amplification of the 
erythroid compartment or the presence 
of RS but on the presence of a mutant 
SF3B1.
Translation of ERFE+12 into a variant 
protein that represses hepcidin
Human ERFE encodes a 354–amino acid 
polypeptide. The addition of 12 nt in 
ERFE mRNA generates an ERFE variant 
(further referred to as ERFEVPFQ) con-
taining a valine-proline-phenylalanine- 
glutamine (VPFQ) insertion immediately 
upstream of the collagen domain (Fig. 4A 
and fig. S5A). To investigate whether the 
mutant ERFEVPFQ protein was produced 
in vivo, we prepared cell lysates of eryth-
roblasts derived in culture from the BM 
CD34+ cells of patients with SF3B1MUT 
MDS. Through liquid chromatography– 
tandem mass spectrometry (LC MS/MS) 
protein identification, we obtained several 
peptide-matching propositions including 
the ALHELGVYYLPDAEGAFR peptide 
(fig. S5B) already reported in public data-
bases (www.proteomicsdb.org), and we 
identified a cryptic peptide VPFQ-
FGLPGPPGPPGPQGPP GPIIPPEALLK 
corresponding to the VPFQ insertion at 
position 108 of ERFE (Fig. 4B). This 
confirms that the alternative ERFE+12 
transcript is translated into ERFEVPFQ in 
SF3B1MUT erythroblasts.
Fig. 2. Differential splice junctions in SF3B1MUTMDSs. (A) Hierarchical clustering and heat map of differential splice 
junctions between SF3B1MUT and SF3B1WT MDS samples. Values indicating percent usage of the differential splice 
junction versus all other junctions sharing the same ss are normalized as Z scores across patients and limited to a 
maximum of |Z| = 2. Rows are splice junctions with indicated types: acceptor (red), donor (blue), ambiguous (green), 
and differentially expressed canonical junction (gray). Columns are patients. (B) Venn diagram of the number of dif-
ferential alternative 5′ donor and 3′ acceptor junctions in SF3B1MUT compared to SF3B1WT MDS. The overlapping area 
represents ambiguous junctions (n = 185). (C) Distances between the alternative (AG′) and canonical (AG) 3′ss within 
the 50 nt upstream of the AG plotted as a histogram. (D) Comparison of the expression of alternative junctions. The 
ratio AG′/AG′ + AG for each junction in SF3B1MUT (red) versus SF3B1WT (gray) MDS is shown. (E) Distribution of the bio-
logical functions of 63 genes affected by one or two aberrant 3′ss junctions located at <50 bases of the canonical 3′ss, 
an additional sequence multiple of 3 nt, a ratio AG′/(AG′ + AG) > 0.1 in SF3B1MUT samples, and an FC > 10. (F) Ratio of 
AG′/(AG′ + AG) in 26 genes whose expression was up- or down-regulated in patients with SF3B1MUT. (G) Sashimi plot 
of 3′ss canonical (*) and aberrant (**) junctions in the FAM132B/ERFE gene in three BM MNC samples, one SF3B1WT and 
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ERFE represses hepcidin in mice and contributes to pathological 
hepcidin suppression in patients with transfused and nontransfused 
-thalassemia (26, 27). Whether ERFEVPFQ also repressed hepcidin 
was tested. For this purpose, recombinant proteins ERFEWT and 
ERFEVPFQ were produced in human embryonic kidney (HEK) 293F 
cells. SDS–polyacrylamide gel electrophoresis analysis of ERFEWT 
and ERFEVPFQ in reducing and nonreducing conditions demon-
strated that the insertion of four amino acids does not change the 
molecular weight of the protein or its multimerization pattern, such 
that both proteins were predominantly found in high–molecular 
mass forms (>250 kDa) and in a trimeric form of ~200 kDa (Fig. 4C). 
Then, Hep3B and HepG2 hepatocellular carcinoma cells were treated 
for 16 hours with purified ERFEVPFQ or ERFEWT. Both proteins 
similarly caused a fivefold reduction in the expression of HAMP 
mRNA encoding hepcidin compared to controls (Fig. 4D). These 
data indicate that insertion of four amino acids upstream of the col-
lagen domain did not affect the bioactivity of the protein.
Prediction of hyperferritinemia by overproduction of ERFE 
in SF3B1MUT MDS
We then measured the plasma concentration of ERFE in the training 
cohort of 156 patients with MDS and 20 healthy non–blood donor 
Fig. 3. SF3B1-dependent expression of 3′ss 
aberrant ERFE+12. (A) Induction of ERFE+12 by 
expressing SF3B1K700E in human SF3B1WT UT-7/
EPO cell line. Cells were transfected with a pLVX 
plasmid encoding a synthetic SF3B1WT or SF3B1K700E 
cDNA. Nontransfected (NT) UT-7/EPO cells are 
shown as a control. The canonical ERFE and aberrant 
ERFE+12 transcripts were detected by capillary 
electrophoresis of fluorescent PCR products. The 
x axis represents molecular size (nt for nucleotides) 
of PCR amplicons, and the y axis represents rela-
tive fluorescent units (RFU). The peak at 150 nt 
corresponds to the canonical transcript, whereas 
the peak at 162 nt refers to the alternative tran-
script due to cryptic AG′ usage. (B) Analysis of 
alternative AG′ and canonical AG usage of ERFE 
and ENOSF1 minigenes transfected into murine 
CRISPR-Cas9 SF3B1WT (clone 9.2) and SF3B1K700E 
(clone 5.13H) G1E-ER4 cells by fluorescent PCR. 
Transfected and NT parental G1E-ER4 cells are 
shown as controls. The peak at 135 nt corre-
sponds to the transcript generated by a canonical 
AG usage, whereas the peak at 147 nt refers to 
the alternative transcript due to cryptic AG′ usage. 
(C) Detection of ERFE+12 depends on the presence 
of an SF3B1 mutant in MDS. BM MNC RNAs from 
three patients with SF3B1 mutations (SF3B1K700E, 
SF3B1H622Q, and SF3B1N626D), three with mutations 
in other splice genes (U2AF1Q157P, SRSF2P95H, and 
ZRSR2H191Y), and three with IDH1R132C, ASXL1dupG646, 
or no mutations were analyzed. ERFE+12/ERFE+12 + 
ERFEWT ratios are indicated. (D) Quantification of 
ERFEWT and ERFE+12 transcripts by RT-qPCR in BM 
samples depicted in (C). Results are expressed as 
normalized ratio quantities (NRQ) to ACTB and 
B2M housekeeping genes. (E) Detection of ERFEWT 
and ERFE+12 transcripts in SF3B1MUT or SF3B1WT 
erythroid progenitors or basophilic/polychromatic 
erythroblasts (Baso/polyE) in culture in comparison 
with BM MNC. (F) Analysis of ERFE transcripts in 
SF3B1WT diseases with ineffective erythropoiesis. 
The image shows peripheral blood (PB) MNC from 
one patient with MDS-RS with TET2 and SRSF2 and 
no SF3B1 mutations, samples from three patients 
with congenital sideroblastic anemias (two BM sam-
ples with ALAS2 mutation and one PB sample with 
GLRX5 mutation), and one PB sample from a patient 
with severe -thalassemia (-Thal). Samples were 
analyzed by capillary electrophoresis of ERFE PCR 
products. One PB sample from a patient with 
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controls using a validated immunoassay (27). We first verified that the 
ERFE immunoassay was able to detect both ERFEWT and ERFEVPFQ. 
Human ERFE enzyme-linked immunosorbent assay (ELISA) detected 
similar amounts (1 g/ml) of each recombinant protein in the 
supernatants of HEK293F cells transiently transfected with ERFEWT 
and ERFEVPFQ expression vectors. This established that both iso-
forms were detectable by ELISA. The mean concentration of ERFE 
in SF3B1MUT or SF3B1WT MDS was higher than that in 20 non–blood 
donor healthy controls (P < 0.0001; Fig. 5A). Among the MDS samples, 
the ERFE concentration was higher in SF3B1MUT (135.0 ± 72.5 ng/ml) 
compared to SF3B1WT (62.1 ± 36.7 ng/ml) 
MDS (P < 0.0001; Fig. 5A). High con-
centrations of circulating ERFE correlated 
with high expression of ERFE+12 transcript 
(Pearson test; P < 0.0001; fig. S6A). Con-
sistently, the ERFE concentration was 
also higher in MDS-RS compared to all 
other World Health Organization (WHO) 
MDS subtypes (fig. S6B). Ferritin con-
centrations were significantly higher in 
patients with SF3B1MUT compared to pa-
tients with SF3B1WT (P < 0.0001; Fig. 5B). 
We also measured plasma hepcidin and 
confirmed that the concentration of 
hepcidin in SF3B1MUT MDS was signifi-
cantly lower compared to SF3B1WT MDS 
(P = 0.031; Fig. 5C). We found no dif-
ference between SF3B1MUT MDS and 
healthy controls. The hepcidin/ferritin 
ratio was lower in SF3B1MUT than in 
SF3B1WT MDS (P < 0.0001; Fig. 5D) and 
also in MDS-RS compared to other WHO 
subtypes (fig. S6C), as a result of both 
a lower concentration of hepcidin and a 
higher concentration of ferritin in pa-
tients with SF3B1MUT. The plasma concen-
tration of ERFE was inversely correlated 
to the hepcidin/ferritin ratio (Pearson 
test; P < 0.0001; r = 0.600; fig. S6D). Our 
analysis also highlights that an ERFE con-
centration above a threshold of 100 ng/ml 
repressed hepcidin more efficiently (fig. 
S6D). Serum EPO concentration was equal-
ly increased in patients with SF3B1MUT 
and SF3B1WT compared to normal values 
(5 to 36 U/liter; table S1), and although 
ERFE is regulated by erythropoietin in 
mice, we did not find any correlation 
between serum EPO and ERFE concen-
tration (fig. S6E) (26). The increased con-
centration of plasma ERFE was associated 
with a more pronounced degree of in-
effective erythropoiesis, as assessed by a 
significant increase in plasma concen-
tration of soluble transferrin receptor 
(sTfR) in SF3B1MUT compared to patients 
with SF3B1WT MDS (P < 0.0001; fig. S6F).
To validate these findings, we pro-
spectively enrolled an external cohort of 
patients with lower-risk MDS in our study until the proportion of 
patients with SF3B1MUT MDS was comparable to that in the train-
ing cohort (table S5). This validation cohort consisted of 55 patients 
with MDS, 42 (76.3%) of whom had MDS with SF3B1 mutation. 
Patients with SF3B1MUT and SF3B1WT in this cohort had a similar 
transfusion burden with a mean number of 4 red blood cell (RBC) 
units per 8 weeks (table S5). The mean concentrations of ERFE and 
ferritin significantly increased (P = 0.0005 and P = 0.0488, respec-
tively; Fig. 5, E and F), whereas hepcidin and hepcidin/ferritin ratio 
significantly decreased in patients with SF3B1MUT (P = 0.0038 and 
Fig. 4. Identification of ERFEVPFQ peptide by mass spectrometry and hepcidin repression by recombinant 
ERFEVPFQ protein. (A) Amino acid sequence of ERFEWT and ERFEVPFQ peptides. VPFQ (red), collagen domain (blue). 
(B) Identification of a specific ERFEVPFQ peptide in erythroblast cell lysates by mass spectrometry using nano liquid 
chromatography coupled with a Q Exactive Plus mass spectrometer. The calculated peptide mass was 3227.650782 
from 3+ ion observed at mass/charge ratio (m/z) 1076.890870 with measured  = 3.6 ppm, Mascot score = 17, expectation 
value = 0.069. HY, hydroxylated proline residues. (C) SDS–polyacrylamide gel electrophoresis and Coomassie blue 
staining of purified ERFEWT and ERFEVPFQ in reducing and nonreducing conditions. (D) Hep3B and HepG2 hepatocellular 
carcinoma cells were treated with purified recombinant human ERFEWT or ERFEVPFQ (2 g/ml) for 16 hours. HAMP was 
quantified by RT-qPCR and normalized to HPRT. Data shown are means ± SEM of three independent experiments and 
represent an FC of hepcidin mRNA expression in ERFE-treated compared to untreated (CTRL) cells. Two-tailed Student 
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P = 0.0002, respectively; Fig. 5, G and H). This confirms the results 
of the training cohort and suggests that the increase of ERFE con-
centration in patients with SF3B1MUT MDS is independent of RBC 
transfusions.
Iron homeostasis changes after RBC transfusions, which amelio-
rate the anemia and increase the concentrations of circulating iron, 
with both effects expected to increase hepcidin. To assess the influ-
ence of RBC transfusion in our analysis, we delineated a subset of 61 
patients with MDS in the training cohort, including 25 patients with 
SF3B1MUT and 36 SF3B1WT with a low transfusion burden before 
inclusion (<4 RBC units per 8 weeks). In this subset, patients with 
SF3B1MUT or SF3B1WT MDS were equally transfused (mean, 0.5 RBC 
unit/8 weeks), but ferritin and plasma iron concentrations remained 
higher in patients with SF3B1MUT (fig. S7, A and B). The hepcidin/
ferritin and hepcidin/plasma iron ratios were significantly lower in 
patients with SF3B1MUT (P < 0.0001 and P = 0.019, respectively; fig. 
S7, C and D), and the circulating ERFE concentration remained 
significantly increased in low transfusion burden patients with 
SF3B1MUT compared to patients with SF3B1WT (P < 0.0001; fig. S7E). 
Erythropoiesis-stimulating agents (ESAs) are used as first-line treat-
ment of anemia, with low serum EPO and low transfusion burden as 
predictors of response (23). We investigated the impact of iron pa-
rameters on the response to epoetin  for 12 weeks in 59 patients with 
low-risk MDS included in a clinical trial of the Groupe Francophone 
des Myélodysplasies (GFM), GFM-Retacrit-2013 (NCT 03598582; 
table S6) (30). Plasma ERFE, ferritin, and hepcidin concentrations 
at enrollment were similar in responding and nonresponding pa-
tients, suggesting that these parameters were not predictive of the 
erythropoietic response in this cohort (fig. S8). We then explored 
the determinants of hyperferritinemia >300 g/ml in patients with 
low transfusion burden. By univariate analysis, ERFE (P = 0.005), 
hepcidin (P = 0.013), and SF3B1 mutation (P = 0.006), but not sTfR 
concentration or the number of transfused RBC units, were signifi-
cantly linked to the concentration of serum ferritin (Table 1). By 
multivariate analysis, ERFE, hepcidin, and SF3B1 mutation remained 
independent predictors of high ferritin concentration (Table 1). 
Together, these results indicate that before patients reach a critical 
threshold of transfusion dependence, hyperferritinemia can be 
caused by SF3B1MUT-induced expression of ERFE, which in turn 
lowers hepcidin.
Erythroid lineage–restricted expression of ERFE+12
In mice, ERFE mRNA expression in the BM is regulated by EPO and 
is predominant in basophilic and polychromatic erythroblasts (26). To 
investigate whether ERFE and ERFE+12 expression is restricted to the 
erythroid lineage, we amplified in parallel the erythroid and granulo-
cytic precursors derived from the BM CD34+ cells of one SF3B1MUT 
and one SF3B1WT sample. The purity of each lineage was assessed 
by the cytological examination of May-Grünwald-Giemsa–stained 
cytospins, and the quantification of lineage-restricted markers was 
assessed by RT-qPCR (Fig. 6A and fig. S9A). To compare the amount 
of each transcript isoform at the different stages of differentiation, 
we quantified the canonical ERFEWT and the aberrant ERFE+12 by 
RT-qPCR. The expression of the canonical transcript ERFEWT ex-
pressed as normalized ratio quantities (NRQ) increased in both 
SF3B1MUT and SF3B1WT MDS erythroblasts. In granulocytes, the 
expression of ERFEWT was close to the limit of detection (Fig. 6B). 
The expression of ERFE+12 was restricted to the erythroid lineage, 
increased with the differentiation of SF3B1MUT erythroblasts, and 
was higher in SF3B1MUT compared to SF3B1WT erythroblasts (Fig. 6B). 
These results indicate that ERFE+12 expression is specific to the 
erythroid lineage.
The SF3B1 gene is mutated in 15% of patients suffering from CLL, 
and the SF3B1MUT allele is present in CD19+ lymphocytes (14, 31). 
To investigate whether ERFE+12 was detectable in SF3B1MUT CLL, 
we collected one sample from a patient with CLL followed by MDS, 
whose BM MNC expressed a clonal SF3B1K700E mutation, and three 
peripheral blood (PB) MNC samples from two patients with CLL, 
one of whom harbored a clonal SF3B1T663I mutation with a variant 
allele frequency of more than 40% and the second had no mutation 
Fig. 5. Increased plasma concentration of ERFE in patients with SF3B1MUT MDS. 
Quantitative analysis was performed in plasma samples collected from 20 non–
blood donor healthy volunteers (black), 156 patients with MDS including 94 SF3B1MUT 
(red) and 62 SF3B1WT (gray) representing the training cohort (A to D), and 55 
patients with MDS including 42 SF3B1MUT (red) and 13 SF3B1WT (gray) representing 
the validation cohort (E to H). The graphs show quantification of erythroferrone 
(A and E), ferritin (B and F), hepcidin (C and G), and hepcidin/ferritin ratio (D and H). 
Results are expressed as medians and interquartile ranges (IQRs). The boxplots 
represent the median and the first and third quartiles, and the whiskers represent 
the lowest and the highest values still within the 1.5 IQR of the lower and upper 
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in the SF3B1 gene, and from a patient with SF3B1K700E MDS. We 
analyzed the MAP3K7 transcript, which is alternatively spliced in 
SF3B1MUT CLL or MDS using a cryptic 3′ss (14, 32). A 170-nt frag-
ment corresponding to the alternative MAP3K7 transcript was en-
riched in all SF3B1MUT samples compared to the SF3B1WT CLL 
(Fig. 6C). ERFE+12 was detected in the PB MNC of the SF3B1K700E 
MDS but not in the SF3B1T663I or SF3B1WT CLL. ERFE+12 was not 
detected in the BM MNC of the SF3B1K700E CLL + MDS sample. To 
get further insights into the cell types expressing ERFE+12, we sorted 
CD19+CD5− B cells, CD19+CD5+ pathological B cells, and CD3+ 
T cells and myeloid cells containing erythroblasts from the BM MNC 
fraction of the patients with SF3B1K700E CLL + MDS, SF3B1K700E 
MDS, and SF3B1WT MDS and from the PB MNC of the patient with 
SF3B1T663I CLL (fig. S9B). The number of cells in the myeloid frac-
tion of SF3B1T663I CLL was too small for further studies. The 170-nt 
fragment of MAP3K7 was detected in CD19+CD5+ pathological 
B cells of SF3B1K700E CLL + MDS and SF3B1T663I CLL and also in the 
myeloid fraction but not in the CD19+CD5− B cells of SF3B1K700E 
MDS (Fig. 6D). By sequencing SF3B1 RNA, we demonstrated that the 
mutation was present in the cell populations in which the alternative 
MAP3K7 transcript was detected (Fig. 6E). The alternative ERFE+12 
transcript was not detected in the CD19+CD5+ pathological B cells 
of SF3B1K700E MDS + CLL or SF3B1T663I CLL, and its expression was 
restricted to SF3B1K700E myeloid MDS cells. Together, these results 
indicate that ERFE is expressed in erythroid cells and ERFE+12 is 
restricted to SF3B1MUT MDS myeloid cells.
Correlation between changes in ERFE+12 expression 
and the response to lenalidomide
Fifty percent of patients with lower-risk MDS, including patients 
with MDS-RS, experience primary resistance or secondary failure 
to treatments they receive to cure their anemia. Whether the mecha-
nism of resistance involves the persistence of clonal erythropoiesis 
is always unknown. We have previously shown that lenalidomide 
administered to patients with ESA-resistant non-del(5q) MDS targets 
the malignant clone and, in some cases, eliminates the dominant 
SF3B1MUT clone for the duration of response (33). However, the fre-
quency of the SF3B1 variant allele, which is expressed in erythroid 
and myeloid cells, does not only reflect the abundance of clonal 
erythroblasts. Here, we retrospectively monitored the expression of 
erythroid-specific ERFE+12 transcript for the follow-up of patients 
included in clinical trials of the GFM: GFM-Retacrit-2013 and 
GFM-LenEpo-2008 (30, 34). For this purpose, we performed a fluo-
rescent PCR and integrated ERFE+12 and ERFEWT peak heights as a 
ratio ERFE+12/ERFE+12 + ERFEWT in patients with SF3B1MUT MDS. 
Then, the ratio was measured in paired RNA samples at enrollment 
and first evaluation. In GFM-Retacrit-2013, four nonresponders and 
six responders were compared, and no significant variation was ob-
served (Fig. 7A and fig. S10A). By contrast, in GFM-LenEpo-2008, 
the ratio ERFE+12/ERFE+12 + ERFEWT decreased in six responding 
patients but remained stable in eight nonresponding patients (Fig. 7B 
and fig. S10B). The percent variation of ratios between samples ob-
tained during screening and after four cycles of treatment was sig-
nificantly different between responding and nonresponding patients 
(Mann-Whitney test, P = 0.0013; Fig. 7B, right). The percent varia-
tion of SF3B1 variant allele frequency in BM MNCs between screen-
ing and evaluation after four cycles was not significantly different 
between nonresponding and responding patients (fig. S10C). This 
confirms that lenalidomide may target clonal erythropoiesis. By 
contrast, ERFE protein quantities did not vary with the response in 
both cohorts (fig. S11). Last, we addressed the prognostic value of 
the ERFE+12/ERFE+12 + ERFEWT ratio for overall survival (OS) in a 
cohort of 90 patients with low-risk MDS, including 24 patients with 
SF3B1MUT and 66 with SF3B1WT enrolled at diagnosis with a median 
follow-up of 36.9 months (table S7). In this cohort, a receiver operating 
characteristic (ROC) analysis established that a value of 0.008 was 
the threshold of positivity of the ERFE+12/ERFE+12 + ERFEWT ratio 
with a specificity and sensitivity of 100%. As shown in Fig. 7C, an 
ERFE+12/ERFE+12 + ERFEWT ratio > 0.008 was predictive of better 
OS (log-rank test; P = 0.019) and was correlated with the presence of 
an SF3B1 mutation. Among patients expressing the variant ERFE+12 
transcript, there was no significant correlation between ERFE+12/ 
ERFE+12 + ERFEWT ratio and OS (log-rank test; P = 0.064; fig. S12). 
Our results suggest that ERFE+12 expression may correlate with OS 
for patients with SF3B1MUT MDS.
DISCUSSION
In this study, we show that in patients with SF3B1MUT MDS, an alter-
native FAM132B/ERFE+12 transcript is translated into an ERFEVPFQ 
Table 1. Erythroferrone, hepcidin, and SF3B1 mutation as independent predictors of hyperferritinemia in low transfusion burden patients with MDS.  
Erythroferrone, hepcidin, sTfR, number of RBC units per 8 weeks, and SF3B1 mutation were evaluated in the group of 60 patients receiving less than 4 RBC units 
per 8 weeks on the basis of ferritin with a cutoff value of 300 ng/ml. Parameters are indicated as means and 95% confidence intervals (95% CI) or ranges. For 
univariate analysis, Mann-Whitney and 2 tests were used to compare the variables between SF3B1MUT and SF3B1WT MDS. Multivariate logistic regression 
analysis was performed for variables with P value < 0.1 in univariate analysis. 
Parameters Ferritin < 300 ng/ml Ferritin ≥ 300 ng/ml Univariate Multivariate
n = 19 n = 41 P value P value
Erythroferrone (ng/ml), 
mean (95% CI)
36.7 (26.8–46.6) 72.7 (55.4–90.0) 0.005 0.002
Hepcidin (ng/ml), mean 
(95% CI)
17.2 (11.2–23.2) 35.9 (25.9–45.9) 0.013 <0.0001
sTfR (ng/ml), mean (95% CI) 1.21 (0.99–1.43) 1.42 (1.18–1.65) 0.484
Number of RBC units/ 
8 weeks, mean (range)
0.2 (0–2) 0.6 (0–3) 0.104
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protein and, together with the canonical 
transcript, contributes to the overexpres-
sion of ERFE. Similarly to ERFE, the 
ERFEVPFQ protein efficiently represses 
hepcidin. ERFE+12 is specifically induced 
by the clonal erythropoiesis.
In SF3B1MUT cancers, alternative 3′ss 
usages are the most frequent splicing 
aberrancies (11, 13, 14, 35). The recently 
resolved crystal structure of the SF3b 
complex helps to understand this feature 
(36). In the spliceosome, the SF3b com-
plex interacts with the pre-mRNA and 
is involved in the branch site selection 
during splicing. Mutations in SF3B1 
affect the structure of the SF3b RNA- 
binding platform, resulting in the se-
lection of alternative branch site and 
alternative transcripts, of which more than 
50% are subjected to NMD (11, 13, 36). 
On the basis of these findings, we focused 
our attention on the transcripts generated 
by the use of an alternative AG′. The anal-
ysis of the distance separating AG from 
AG′ revealed strong peaks at 15, 18, and 
21 nt, showing that inserts could be 
multiples of 3 nt. Among alternative in-
frame junctions, we identified two reg-
ulators of iron homeostasis, ABCB7 and 
ERFE. As already reported, the alternative 
ABCB7 mRNA results from the addition 
of 21 nt between exons 8 and 9 and, in our 
sample set, was slightly down-regulated 
in SF3B1MUT compared to SF3B1WT MDS 
(11, 32, 37). By contrast, the aberrant ERFE 
transcript modified by the addition of 12 nt 
was up-regulated 2.3-fold in SF3B1MUT 
MDS. ERFE+12 has not been reported in 
other SF3B1MUT cancers despite some over-
lap between the sets of alternative 3′ss 
transcripts in SF3B1MUT uveal melano-
ma, CLL, and MDS (11, 13, 14, 38, 39). 
We showed the existence of a variant 
protein containing VPFQ sequence im-
mediately upstream of the collagen 
domain, which is putatively involved in 
protein- protein interactions in other 
CTRP family members (40). VPFQ may 
not influence protein conformation, 
because the apparent molecular weight 
was similar for recombinant ERFEWT 
and ERFEVPFQ proteins, which both re-
pressed HAMP gene expression. How-
ever, we could not exclude an effect of 
the VPFQ insertion on protein stability 
and/or still unknown functions.
In MDS, serum EPO is increased but 
ineffective in stimulating erythropoiesis 
because maturing erythroid cells undergo 
Fig. 6. Erythroid cell-restricted expression of ERFE+12. (A) May-Grünwald-Giemsa–stained cytospins of erythroid 
and granulocytic precursors obtained from liquid culture of BM SF3B1WT or SF3B1K700E CD34+ progenitors. (B) Quantification 
of ERFEWT and ERFE+12 in erythroid and granulocytic precursors by RT-qPCR. Results are expressed as NRQ ± SEM to ACTB 
and B2M housekeeping genes. (C) ERFE+12 is absent in SF3B1MUT CLL. BM MNCs from a patient with SF3B1K700E CLL + MDS 
or PB MNCs from patients with SF3B1T663I CLL, SF3B1WT CLL, and SF3B1K700E MDS were collected for analysis by capillary 
electrophoresis of ERFE and MAP3K7 fluorescent PCR products. ERFE+12 was detected as a 162-nt fragment and 
MAP3K7+20 was detected as a 170-nt fragment. PB samples from one patient with an SF3B1WT CLL and one patient 
with an SF3B1MUT MDS are shown as controls. (D) ERFE+12 expression is restricted to SF3B1MUT myeloid lineage. 
CD19+CD5− B cells, CD19+CD5+ B CLL cells, CD3+ T cells, and myeloid cells were sorted from the BM MNC fraction of 
an SF3B1K700E CLL + MDS, an SF3B1K700E MDS, and an SF3B1WT MDS and from the PB MNCs of an SF3B1T663I CLL. ERFE 
and MAP3K7 transcripts were analyzed by fluorescent PCR. (E) The sequencing of SF3B1 was performed on cDNA of 
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apoptosis in terminal phases of differentiation (1, 2). Increased EPO 
and sTfR concentrations have been inversely correlated with hepcidin 
concentrations in MDS (17, 18, 41, 42). Our study indicates that 
plasma hepcidin concentration in SF3B1MUT MDS is similar to healthy 
non–blood donor controls and inappropriately low compared to 
SF3B1WT MDS, suggesting that its production could be dysregulated 
by severe ineffective erythropoiesis and/or a more specific mecha-
nism (17). We showed the cell-autonomous SF3B1MUT-dependent 
expression of ERFE+12 and a role for increased concentrations of 
circulating ERFE in hepcidin reduction. 
This confirms the involvement of ERFE 
in human pathologies (27).
ERFE is the major erythroid regulator 
of hepcidin (26). Other candidate regu-
lators of hepcidin linked to erythropoiesis 
have been proposed, including EPO and 
GDF-15. Although EPO administration 
decreases hepcidin concentration (43), 
this effect is predominantly indirect. The 
other candidate, GDF-15, is poorly in-
duced by EPO in human volunteers. Al-
though serum GDF-15 concentration was 
increased in -thalassemia or congenital 
dyserythropoietic anemia, it was not 
inversely correlated with hepcidin in 
MDS (17, 24, 44). Low hepcidin preserves 
ferroportin on enterocytes and macro-
phages, causing increased intestinal ab-
sorption and macrophage release of iron 
(45, 46). Compared to SF3B1WT MDS, 
the lower concentrations of hepcidin in 
SF3B1MUT MDS may explain early iron 
overload before patients receive erythro-
cyte transfusions (17, 18). In patients with 
low transfusion burden, who had received 
a mean of 0.5 RBC units, hepcidin, ERFE, 
and SF3B1 mutation were independent 
predictors of hyperferritinemia. This 
demonstrates that iron overload is strongly 
related to the control of hepcidin through 
the SF3B1-regulated production of ERFE. 
Hepcidin increases with transfusion inten-
sity in patients with MDS or -thalassemia 
because of exogenous iron loading and 
transient suppression of ineffective eryth-
ropoiesis (27, 47, 48). Here, in regularly 
transfused patients with SF3B1MUT MDS, 
hepcidin remained lower and ERFE 
remained higher than in patients with 
SF3B1WT MDS. This establishes a driver 
role for SF3B1 mutation in the stimula-
tion of ERFE expression and systemic iron 
overload that characterized patients.
The SF3B1 mutation confers a good 
prognosis in MDS (6, 49). However, when 
patients are transfusion dependent, iron 
overload in cardiac and liver tissues 
becomes clinically evident and may im-
pair life expectancy (50). Chelation effi-
ciently reduces iron burden in regularly transfused patients with MDS 
and serves as an adjuvant therapy for anemia, because deferasirox 
may improve hematopoiesis by protecting against oxidative stress 
(51–53). Promising substitutes for ESAs in resistant patients include 
lenalidomide, which may transiently reduce SF3B1 mutant allele bur-
den, and activin receptor ligand traps such as luspatercept, which promotes 
late-stage erythropoiesis in mouse models of -thalassemia and MDS 
and diminishes iron overload in -thalassemia mice (33, 54–56). In 
lenalidomide-treated patients, but not in epoetin –treated patients, 
Fig. 7. ERFE+12 expression as a marker of clonal erythropoiesis and survival. Fluorescent PCR was performed at 
screening and evaluation in (A) 10 paired samples from patients with SF3B1MUT MDS enrolled in the GFM-Retacrit-2013 
clinical trial (four nonresponding and six responding patients) and (B) 14 paired samples from patients with SF3B1MUT 
MDS enrolled in the GFM-LenEpo-2008 clinical trial (eight nonresponding and six responding patients). Peak heights 
of ERFE+12 and ERFEWT signals were integrated as ERFE+12/ERFE+12 + ERFEWT ratios. Percent variations of ratios are indicated 
(right) as medians and IQR (25 to 75%). Mann-Whitney test for P values. (C) Overall survival according to ERFE+12/ERFE+12 + 
ERFEWT ratio shown as a Kaplan-Meier curve. A threshold of positivity of 0.008 was determined by ROC analysis. Log-rank 
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the kinetics of ERFE+12 expression correlated with the response to treat-
ment, indicating that in responding patients, lenalidomide targeted 
clonal erythroid precursors either directly or indirectly. Changes 
in plasma ERFE protein after lenalidomide were not correlated with 
the response to these treatments. The impact of transfusions on the 
regulation of ERFE expression at the post-transcriptional level should 
be examined in the future. ERFE+12 expression could also be useful 
for disease surveillance of patients with MDS-RS treated with other 
drugs, such as luspatercept. Further clinical studies will be required 
to validate ERFE+12 expression as a therapy-responsive biomarker of 
ineffective erythropoiesis in patients with SF3B1MUT MDS.
Last, our findings open therapeutic avenues for preventing iron 
accumulation in patients with MDS-RS. Increasing hepcidin could 
produce therapeutic benefits in SF3B1MUT MDS, because a moder-
ate increase in hepcidin decreased iron and improved anemia in 
-thalassemia mice (57). Therefore, either the administration of a 
hepcidin agonist or the targeting of ERFE overexpression may pro-
vide a potential strategy for preventing iron overload and improving 
erythropoiesis in patients with SF3B1MUT MDS.
MATERIALS AND METHODS
Study design
The study involved identifying a splicing variant of ERFE by RNA- 
sequencing human primary BM samples and the variant peptide by 
mass spectrometry. Each in vitro experiment (transfection, minigene 
assay, Degron-KI, transcriptional repression of hepcidin) was 
repeated three times. Each experiment using primary cells was per-
formed with at least three samples in each category. A ratio of ERFE 
variant transcript to total transcript was validated as a marker of 
clonal erythropoiesis on the basis of the response to lenalidomide or 
ESA in two cohorts of patients with MDS enrolled in clinical trials 
and as a prognostic marker of OS in a prospective multicenter cohort 
of patients with MDS. Predictive value of plasma ERFE and hepcidin 
concentrations for hyperferritinemia was measured in training and 
validation cohorts of patients with MDS. For these studies, ran-
domization or blinding was not applicable.
Patients
For the training cohort, patients with MDS (n = 156) were enrolled 
between 2008 and 2017 (ClinicalTrials.gov: GFM-LenEpo-2008, 
NCT01718379; GFM-Retacrit-2013, NCT 03598582). For the 
GFM-Retacrit-2013 cohort, the status of response to epoetin  was 
recorded. The prospective cohort of 90 patients with MDS with survival 
data was enrolled between 2010 and 2018. BM aspirates and PB plasma 
samples were collected after each patient gave informed consent for 
biological investigations according to the recommendations of the 
institutional review boards (IRBs): IdF X GFM-LenEpo-08 EudraCT 
2008-008262-12, IdFII 2010-A00033-36, IdFIII 2010-2753, IdFV 
212-A01395-38 EudraCT 2012-002990-7338, and OncoCCH 2015-
08-11-DC. For the validation cohort, patients with MDS (n = 55) 
were enrolled prospectively for plasma collection in France (five 
centers; IRB Onco-CCH 2015-08-11 DC) and Germany (one center; 
IRB Ethikkommission an der TU Dresden; EK 115032015) between 
2016 and 2018. BM samples from five age-matched controls and PB 
plasma samples from 20 healthy controls were collected. Patient 
characteristics are indicated in tables S1, S5, and S7 and according 
to the response to epoetin  in table S6. Low transfusion burden was 
defined as <4 RBC units per 8 weeks.
DNA and RNA sequencing
Mutations in a panel of 26 genes were screened by next-generation 
sequencing (NGS) (fig. S1). RNA was sequenced on an Illumina 
HiSeq 2500 platform using a 100–base pair paired-end sequencing 
strategy. TopHat (v2.0.6) was used to align the reads against the 
human reference genome Hg19 RefSeq (RNA sequences, GRCh37) 
downloaded from the University of California, Santa Cruz Genome 
Browser (http://genome.ucsc.edu). Analyses of differential gene ex-
pression and differential junction read counts were performed using 
DESeq2 (13, 28).
CRISPR-Cas9 generation of isogenic Sf3b1K700E and Sf3b1WT 
cell lines
The murine erythroid cell line G1E-ER4 (58) was used to generate 
isogenic Sf3b1K700E and Sf3b1WT cell lines using CRISPR-Cas9–
stimulated homology-mediated repair.
ERFE and ENOSF1 minigenes
The ERFE minigene was synthesized by insertion of the ERFE alter-
native junction in pET01 Exontrap vector (MoBiTec). G1E-ER4 9.2 
(SF3B1WT) and G1E-ER4 5.13H (SF3B1K700E) cells were transfected 
and processed for fluorescent PCR.
Mass spectrometry analysis
Erythroblasts were lysed, and peptides were obtained by trypsin diges-
tion (Promega) and analyzed by nano liquid chromatography coupled 
with a Q Exactive Plus mass spectrometer (Thermo Fisher Scientific). 
Data were analyzed using Mascot 2.5.1 (www.matrixscience.com).
Human ERFE quantification
Plasma ERFE concentration was determined as previously described (27).
Statistical analysis
For quantitative variables, values were compared using the Mann- 
Whitney test. Categorical variables were compared using 2 or Fisher’s 
exact tests. P values < 0.05 were considered significant. ROC analysis 
was used to calculate the thresholds of positivity. Multivariate logistic 
regression analysis was adjusted for selected variables chosen with 




Fig. S1. Genomic characteristics of the training cohort of 156 patients with MDS.
Fig. S2. Identification of in-frame alternative transcripts in SF3B1MUT MDS samples by RNA 
sequencing.
Fig. S3. Allele-specific investigation of mutant SF3B1 causal relationship to aberrantly spliced 
ERFE+12 transcript using Degron-KI strategy.
Fig. S4. Massive use of FAM132B/ERFE cryptic junction in one MDS-RS with a bi-allelic alteration 
of the SF3B1 gene.
Fig. S5. Identification of ERFE peptide by LC MS/MS.
Fig. S6. Correlation of plasma ERFE concentrations with ERFE+12 transcript, WHO classification, 
and iron homeostasis parameters.
Fig. S7. Biological parameters of low transfusion burden patients with MDS in the training 
cohort.
Fig. S8. Plasma ERFE, ferritin, and hepcidin concentrations at enrollment in 59 patients with 
MDS according to the response to EPO.
Fig. S9. Erythroid-specific expression of ERFE variant transcript.
Fig. S10. Variations of ERFE+12 transcript expression SF3B1MUT low-risk MDS after therapy.
Fig. S11. Variations in plasma concentration of ERFE protein in SF3B1MUT low-risk MDS after 
therapy.
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Table S1. Clinical and biological characteristics of the training cohort of 156 patients with MDS 
according to SF3B1 status.
Table S2. Differential expression of ERFE transcripts according to the mutational status of 
SF3B1, TET2, and DNMT3A genes by RNA sequencing.
Table S3. Primer sequences used for fluorescent PCR and RT-qPCR.
Table S4. Expression of total ERFE, ERFEWT, and ERFE+12 transcripts by fluorescent PCR and 
RT-qPCR in nine MDS BM samples.
Table S5. Clinical and biological characteristics of the validation cohort of 55 patients with 
MDS according to SF3B1 status.
Table S6. Clinical and biological characteristics of the cohort of 59 patients with MDS in the 
GFM-Retacrit-2013 cohort according to response status.
Table S7. Clinical and biological characteristics of the cohort of 90 patients with MDS with 
survival data according to SF3B1 and ERFE+12 status.
Data file S1. Differentially expressed transcripts between patients with SF3B1MUT and SF3B1WT 
MDS by RNA sequencing and custom code.
Data file S2. Differentially expressed 5′ and 3′ junctions between patients with SF3B1MUT and 
SF3B1wT MDS by RNA sequencing.
Data file S3. In-frame and differentially expressed 3′ cryptic ss junctions in SF3B1MUT MDS.
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biomarker of clonal hematopoiesis.
Moreover, the variant erythroferrone is not present in healthy bone marrow cells, indicating its potential utility as a
produced in this disorder and results in deregulation of iron loading through suppression of the hormone hepcidin. 
. discovered that a variant form of erythroferrone, a hormone that helps regulate bone marrow function, isal
etknown for causing iron overload even in the absence of transfusions, but the reasons for this are unclear. Bondu 
potential complications. One category of myelodysplastic syndromes, those associated with ring sideroblasts, is 
Myelodysplastic syndromes are clonal disorders of hematopoiesis with a variety of manifestations and
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